At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 807 enrolled
Drug / intervention
Eluxadoline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea
In Brief
A Phase 2 clinical trial evaluating Eluxadoline and Placebo for Irritable Bowel Syndrome. Completed, enrolled 807 participants across 288 sites.
Detailed Summary
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritable Bowel Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedMay 25, 2010
Enrollment StartApr 28, 2010
Primary CompletionJul 14, 2011
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 16.1 years ago
Interventions
Eluxadolinedrug
Tablets, orally, twice daily.
Placebodrug
Matching placebo oral tablets twice daily.